This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2024 Oct;76(5):540-544.

doi: 10.23736/S2724-6051.24.06114-7.

Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?

Chiara Ciccarese¹, Veronica Mollica², Laura Marandino³, Carlotta Palumbo⁴, Riccardo Campi^{5

6}, Daniele Amparore⁷; EAU Young Academic Urologists (YAU) Renal Cancer Working Group

Collaborators, Affiliations

Collaborators

EAU Young Academic Urologists (YAU) Renal Cancer Working Group:
Riccardo Bertolo, Leonardo D Borregales, Anna Caliò, Umberto Carbonara, Pietro Diana, Giulio Francolini, Margue Gaelle, Michele Marchioni, Stijn Muselaers, Nicola Pavan, Angela Pecoraro, Eduard Roussel, Erdem Selcuk, Gopal Sharma, Hannah Warren, Zhenjie Wu

Affiliations

¹ Medical Oncology Unit, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.
² Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - veronica.mollica7@gmail.com.
³ Medical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
⁴ Unit of Urology, Maggiore della Carità Hospital, Novara, Italy.
⁵ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
⁶ Urological Robotic Surgery and Renal Transplantation Unit, Careggi Hospital, University of Florence, Florence, Italy.
⁷ Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.

PMID: 39320246
DOI: 10.23736/S2724-6051.24.06114-7

Free article

Editorial

Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?

Chiara Ciccarese et al. Minerva Urol Nephrol. 2024 Oct.

Free article

. 2024 Oct;76(5):540-544.

doi: 10.23736/S2724-6051.24.06114-7.

Authors

Chiara Ciccarese¹, Veronica Mollica², Laura Marandino³, Carlotta Palumbo⁴, Riccardo Campi^{5

6}, Daniele Amparore⁷; EAU Young Academic Urologists (YAU) Renal Cancer Working Group

Collaborators

EAU Young Academic Urologists (YAU) Renal Cancer Working Group:
Riccardo Bertolo, Leonardo D Borregales, Anna Caliò, Umberto Carbonara, Pietro Diana, Giulio Francolini, Margue Gaelle, Michele Marchioni, Stijn Muselaers, Nicola Pavan, Angela Pecoraro, Eduard Roussel, Erdem Selcuk, Gopal Sharma, Hannah Warren, Zhenjie Wu

Affiliations

¹ Medical Oncology Unit, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.
² Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - veronica.mollica7@gmail.com.
³ Medical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
⁴ Unit of Urology, Maggiore della Carità Hospital, Novara, Italy.
⁵ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
⁶ Urological Robotic Surgery and Renal Transplantation Unit, Careggi Hospital, University of Florence, Florence, Italy.
⁷ Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.

PMID: 39320246
DOI: 10.23736/S2724-6051.24.06114-7

No abstract available

PubMed Disclaimer

Similar articles

Do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years.
Rojas PA, Carracedo D, Moscatiello P, González L, Gimbernat H, Santiago M, Toledo M, Pereira N, Sánchez-Encinas M. Rojas PA, et al. World J Urol. 2025 May 16;43(1):307. doi: 10.1007/s00345-025-05599-0. World J Urol. 2025. PMID: 40377723
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Clinical Trial.
Adjuvant Pembrolizumab in Renal-Cell Carcinoma. Reply.
Choueiri TK, Powles T. Choueiri TK, et al. N Engl J Med. 2024 Jul 11;391(2):186. doi: 10.1056/NEJMc2406031. N Engl J Med. 2024. PMID: 38986066 No abstract available.
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
Fleeman N, Houten R, Nevitt S, Mahon J, Beale S, Boland A, Greenhalgh J, Edwards K, Maden M, Bhattacharyya D, Chaplin M, McEntee J, Chow S, Waddell T. Fleeman N, et al. Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238. Health Technol Assess. 2024. PMID: 39252678 Free PMC article.
Adjuvant treatment for renal cell carcinoma: current status and future.
Leung DKW, Siu BWH, Teoh JYC. Leung DKW, et al. Curr Opin Urol. 2025 Jan 1;35(1):41-45. doi: 10.1097/MOU.0000000000001229. Epub 2024 Sep 17. Curr Opin Urol. 2025. PMID: 39298572 Review.

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Minerva Medica
Medical
- MedlinePlus Health Information